ArticleHuman brain mapping2020
Longitudinal validity of PET-based staging of regional amyloid deposition.
Article in Human brain mapping, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer's pathology.Alzheimer's research & therapy · 2025Review
- Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study.European journal of nuclear medicine and molecular imaging · 2025Article
- Brain Topological Changes in Subjective Cognitive Decline and Associations with Amyloid Stages.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Exploration of neuroanatomical characteristics to differentiate prodromal Alzheimer's disease from cognitively unimpaired amyloid-positive individuals.Scientific reports · 2024Article
- Biomarker-based staging of Alzheimer disease: rationale and clinical applications.Nature reviews. Neurology · 2024Review
- Alterations in Gut Microbiota and Their Correlation with Brain Beta-Amyloid Burden Measured byJournal of clinical medicine · 2024Article
- The use of neuroimaging techniques in the early and differential diagnosis of dementia.Molecular psychiatry · 2023Review
- The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Review
- A unique color-coded visualization system with multimodal information fusion and deep learning in a longitudinal study of Alzheimer's disease.Artificial intelligence in medicine · 2023Article
- Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers.Nature communications · 2023Article
- Neurodegenerative and Cerebrovascular Brain Pathologies Are Differentially Associated With Declining Grip Strength and Gait In Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78-94.Molecular psychiatry · 2022Article
- Rates of β-amyloid deposition indicate widespread simultaneous accumulation throughout the brain.Neurobiology of aging · 2022Article
- Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support.Alzheimer's research & therapy · 2021Article
- In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease.Alzheimer's research & therapy · 2021Article
- The role of APOE in cognitive trajectories and motor decline in Parkinson's disease.Scientific reports · 2021Article
- Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.Frontiers in aging neuroscience · 2021Article
- Longitudinal validity of PET-based staging of regional amyloid deposition.Human brain mapping · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Positron emission tomography (PET)-based staging of regional amyloid deposition has recently emerged as a promising tool for sensitive detection and stratification of pathology progression in Alzheimer's Disease (AD). Here we present an updated methodological framework for PET-based amyloid staging using region-specific amyloid-positivity thresholds and assess its longitudinal validity using serial PET acquisitions. We defined region-specific thresholds of amyloid-positivity based on Florbetapir-PET data of 13 young healthy individuals (age ≤ 45y), applied these thresholds to Florbetapir-PET data of 179 cognitively normal older individuals to estimate a regional amyloid staging model, and tested this model in a larger sample of patients with mild cognitive impairment (N = 403) and AD dementia (N = 85). 2-year follow-up Florbetapir-PET scans from a subset of this sample (N = 436) were used to assess the longitudinal validity of the cross-sectional model based on individual stage transitions and data-driven longitudinal trajectory modeling. Results show a remarkable congruence between cross-sectionally estimated and longitudinally modeled trajectories of amyloid accumulation, beginning in anterior temporal areas, followed by frontal and medial parietal areas, the remaining associative neocortex, and finally primary sensory-motor areas and subcortical regions. Over 98% of individual amyloid deposition profiles and longitudinal stage transitions adhered to this staging scheme of regional pathology progression, which was further supported by corresponding changes in cerebrospinal fluid biomarkers. In conclusion, we provide a methodological refinement and longitudinal validation of PET-based staging of regional amyloid accumulation, which may help improving early detection and in-vivo stratification of pathologic disease progression in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.